How host regulation of *Helicobacter pylori*-induced gastritis protects against peptic ulcer disease and gastric cancer

Poshmaal Dhar\(^1,2\), Garrett Z Ng\(^1,2\) and Philip Sutton\(^{1,2,3}\)#

\(^1\) Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria 3052, Australia

\(^2\) Centre for Animal Biotechnology, School of Veterinary and Agricultural Science, University of Melbourne, Parkville, Victoria 3010, Australia

\(^3\) Department of Paediatrics, University of Melbourne, Parkville, Victoria 3010, Australia

#Correspondence: Associate-Professor Philip Sutton, Mucosal Immunology, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria 3052, Australia. phil.sutton@mcri.edu.au; Ph: +61 3 9936 6751; Fax: +61 3 9936 6528

Author contributions: PD, PS and GZN wrote and edited the manuscript.

Declarations: The authors declare no conflict of interest.
ABSTRACT

The bacterial pathogen *Helicobacter pylori* is the etiological agent of a range of gastrointestinal pathologies including peptic ulcer disease and the major killer, gastric adenocarcinoma. Infection with this bacterium induces a chronic inflammatory response in the gastric mucosa (gastritis). It is this gastritis that, over decades, eventually drives the development of *H. pylori*-associated disease in some individuals. The majority of studies investigating *H. pylori* pathogenesis have focused on factors that promote disease development in infected individuals. However, an estimated 85% of those infected with *H. pylori* remain completely asymptomatic, despite the presence of pathogenic bacteria that drive a chronic gastritis that lasts many decades. This indicates the presence of highly effective regulatory processes in the host that, in most cases, keeps a check on inflammation and protect against disease. In this mini-review we discuss such known host factors and how they prevent the development of *H. pylori*-associated pathologies.

Key words: *Helicobacter pylori*, host factors, gastritis, immune suppression
INTRODUCTION

*Helicobacter pylori* are pathogenic, highly motile, microaerophilic bacteria that colonize the mucus layer lining the human stomach. This highly prevalent infection is usually acquired in childhood and, without antibiotic treatment, will persist throughout the lifetime of the individual, inducing an inflammatory immune response in the gastric mucosa (gastritis). It is this gastritis that, over decades of chronic bacterial-induced immunostimulation, eventually drives the development of *H. pylori*-associated disease in some individuals. *H. pylori* infection is the proven cause of a range of gastrointestinal pathologies, including peptic ulcer disease (gastric and duodenal ulcers) (35), gastric mucosa-associated lymphoid tissue (MALT) lymphoma (63) and gastric adenocarcinoma (60). Due to its high prevalence, particularly in Asia, gastric adenocarcinoma is globally the 3rd leading cause of death due to cancer (22).

The oft-quoted statistic is that approximately 15% of those infected with *H. pylori* develop an associated pathology; the individuals who do develop such a disease are believed those who mount the most severe inflammatory response to this infection. The reason why some individuals develop a more severe gastritis and progress to disease are multi-fold and include infection by more virulent strains of *H. pylori*, the impact of environmental factors such as high salt diet and smoking, as well as the effect of host genetic factors that make certain unfortunate individuals more susceptible to the pathological sequelae of this infection (reviewed in (64)). Understandably, the majority of studies investigating *H. pylori* pathogenesis have focused on factors that promote disease in infected individuals, and these have been the subject of numerous previous reviews.

Rarely considered however, is the other side of the coin. It is a quite remarkable feat perhaps, that the vast majority (an estimated 85%) of people infected with *H. pylori* remain completely
asymptomatic for life, despite the presence of pathogenic bacteria inducing a chronic inflammation over a period of many decades (often 70-80 years). This predominant lack of pathology clearly indicates the presence of highly effective regulatory processes that, at least in most individuals, protect against the pathological consequence of *H. pylori* infection. It is not that asymptomatic individuals do not develop gastritis – to our knowledge no *H. pylori* infected person has ever been reported who does not have gastritis (13) – it is just that the severity of the inflammation can be regulated to a degree that prevents the development of pathology.

For *H. pylori* to induce gastritis, they must first swim through the mucus layers lining the stomach to reach the surface of the gastric epithelial cells, where a proportion of them attach. From this locale, these bacteria trigger the host innate immune system, with a range of consequences including the opening of the tight cell-cell junctions that normally maintain the impermeable epithelial barrier and the recruitment of pro-inflammatory cells including neutrophils and macrophages to the gastric mucosa (1). This is subsequently followed by activation of the adaptive immune response where both Th1 and Th17-type T helper cells have been associated with the development of chronic gastritis (2, 54).

It is worth mentioning here that to co-evolve with the host, *H. pylori* has successfully managed to dampen the immune response elicited against it. Compared with other Gram-negative bacteria, *H. pylori* lipopolysaccharide and flagella are poor activators of the innate signalling pathway mediated via recognition of these bacterial ligands by their specific Toll-like receptors (TLR), making them less immunogenic (51). Additionally, two *H. pylori* virulence factors, vacuolating cytotoxin A and γ-glutamyl transpeptidase promote the development of regulatory T cells (discussed later) to limit inflammation (51), but these bacterial factors are not the focus of this review.
In this current mini-review, we will discuss known host factors that actively inhibit *H. pylori*-induced inflammation and thereby protect the majority of those infected from gastric cancer and peptic ulcer disease. The complex inflammatory response provides multiple stages which can be regulated by the host. Specifically, the *H. pylori* infected individual has evolved to co-exist with this pathogen by developing a number of features which include 1) a mucosal barrier that restricts access of *H. pylori* to the epithelial surface, as well as factors that reduce activation of 2) the innate and 3) the adaptive immune response to this infection. These are further discussed below, and summarized in Table 1.

**The gastric mucosal barrier**

Gastric mucus is composed of two main overlapping layers of secreted mucins. The outer mucus layer contains Mucin 5AC (MUC5AC), which is secreted by surface epithelial mucous cells, while the inner mucus layer predominantly comprises MUC6, which is secreted by mucous neck cells located in the gastric pits. The majority of *H. pylori* are located within the MUC5AC-containing outer mucus layer and are rarely observed within the MUC6-containing layer that lies closest to the epithelial surface (20); only a few of these bacteria contact the epithelial surface. This preferential distribution of *H. pylori* is most likely due to the presence of a number of bactericidal agents within the inner mucus layer. MUC6 has a terminal cap of α-1,4 N-Acetylglucosamine with antibacterial activity that has been shown to inhibit *H. pylori* growth (25). Given the large quantity of MUC6 present in the inner mucus layer, the antibacterial activity of this mucin is likely to be the main explanation for the low levels of *H. pylori* in this region, but other bactericidal agents including antimicrobial peptides like β-defensins-2 (40), cathelicidin LL-37 (66) and galectin-3 (43) might also play a
role (Figure 1A). In summary, due to these bactericidal properties, the inner mucus layer effectively limits the number of *H. pylori* that reach the gastric epithelium, thereby restricting activation of innate immune receptors on the epithelial surface.

2) **Host inhibition of the innate immune response to *H. pylori***

Bacteria that do reach the epithelial surface activate a range of innate immune responses. A number of innate receptors are linked with *H. pylori*-driven gastritis, but perhaps the most important include TLR2, TLR4 and TLR9, the nucleotide binding and oligomerization domain 1 (NOD1), and the NOD-like receptor pyrin domain-containing 3 (NLRP3) receptor (51). Activation of these receptors leads to the induction of intracellular signaling cascades, the majority of which are pro-inflammatory, and normally aimed at clearing the infection. These pathways induce the secretion of cytokines and chemokines (including IL-8, IL-1β, IL-6, IL-12, TNFα) as well as reactive oxygen and nitrogen species, and cyclooxygenase-2. In the case of *H. pylori* however, this innate inflammatory immune response fails to clear the infection and if left unregulated, the sustained and unrestricted inflammation would likely result in disease. Probably for this reason, the host has developed several mechanisms, discussed hereafter, that dampen the innate, inflammatory immune response to *H. pylori*.

*Trefoil factors*

Trefoil factors (TFF) are a family of small (7–12 kDa) protease-resistant proteins that are copiously produced by mucus-secreting cells and which protect mucosal surfaces by promoting epithelial repair and healing (59). Two members of this family, TFF1 and TFF2, are progressively downregulated during human gastric cancer development, consistent with both having roles in limiting inflammation (32), a suggestion supported by animal studies.
whereby mice deficient in either TFF1 or TFF2 were demonstrated to display more severe gastritis after *Helicobacter* infection (29, 58).

TFF1 is found in association with the MUC5AC mucus layer in the stomach, and has also been shown to bind *H. pylori* (10), while TFF2 is located within the MUC6 layer (42). TFF2 also appears to have a biologically relevant role in leukocytes, at least in rodents, as *Tff2*−/− leukocytes in isolation exhibit increased inflammatory activity (29). Interestingly, TFF2 appears to have a role in sustaining TFF1 expression (45), which could mean that TFF2 partially mediates its anti-inflammatory effects through TFF1, although suppressive mechanism(s) distinct from TFF1 have been identified (see below).

Multiple innate cellular receptors and subsequent signaling pathways result in activation of nuclear transcription factor-κB (NF-κB; a “master” transcription factor that plays a major role in the innate immune response), including TLRs and receptors for IL-1 (IL-1R) and TNFα (TNFR) (44). Mechanistically, both TFF1 and TFF2 have been inferred to negatively regulate activation of NF-κB. TFF1 inhibits activation of TNFR1 by preventing signaling intermediates, specifically TRAF2, from binding and thus conducting the signaling cascade (57) (Figure 1B). It remains possible that TFF1 might also inhibit NF-κB activation via other pathways.

TFF2 also appears to inhibit NF-κB activation, as *Tff2*−/− cells produce elevated amounts of NF-κB-driven cytokines after stimulation (29). This appears distinct from TFF1 regulation as it is primarily due to suppression of IL-1R signaling (29) (Figure 1D). However, TFF2 can also inhibit certain aspects of TLR4 signaling, as inducible Nitric Oxide Synthase (iNOS) production in response to TLR4 activation of the RAW264.7 macrophage cell line was suppressed by TFF2 treatment (16).
Gastrokines (GKNs) are small proteins that are almost exclusively expressed in the stomach. Multiple studies have demonstrated a reduction, or loss of expression of GKN1 and GKN2 in gastric cancer, as well as in *H. pylori* infected tissue (reviewed in (37)). While there is some *in vitro* evidence for an effect of GKN1 on cells, it is currently unclear whether these effects translate to a meaningful effect *in vivo*, as GKN1 deficient animals are not available. Hence this will not be discussed here.

Recently, *Gkn2*<sup>−/−</sup> mice were described and convincingly demonstrated to have an accelerated inflammatory phenotype in response to *H. pylori* infection and in genetic models of gastric cancer (38). The immunophenotype of *Gkn2*<sup>−/−</sup> epithelial cells was described to be similar to that of wildtype cells (38). However, interestingly, the immune cells present in *Gkn2*<sup>−/−</sup> stomachs display elevated levels of pro-inflammatory cytokines (TNFα, IL-1α, IL-6, CXCL1, CCL4) and anti-inflammatory IL-10 (which probably prevents spontaneous gastritis), suggesting that GKN2 has an exogenous effect on resident immune cells (Figure 1I). A separate study has suggested that GKN2, when overexpressed, might suppress NF-κB activation (67), which could be one mechanism by which GKN2 mediates *in vivo* effects. However, the mechanism of immunomodulation *in vivo* remains to be determined.

In summary, GKN2 is clearly an important regulatory host factor during *H. pylori* infection. Given this suppressive role, it is likely that GKN2 (and possibly GKN1) act as rheostats to inhibit inflammation during the basal state, and when downregulated as observed during infection or cancer, allow inflammatory responses to pathogens such as *H. pylori*.

**Mucin 1**
MUC1 is a cell membrane-associated mucin, expressed on the majority of mucosal epithelial cells, as well as most immune cells. Like all mucins, MUC1 contains an extracellular VNTR (variable number of tandem repeats) region, which produces a high degree of polymorphism in molecule length. Epidemiological studies found that short MUC1 alleles were associated with an increased susceptibility to both gastric cancer (6) and chronic H. pylori gastritis (61). This established MUC1 as a potential protective host factor in H. pylori pathogenesis, a possibility confirmed when it was shown that mice lacking MUC1 were not only colonized by increased numbers of H. pylori, but also developed a considerably more severe gastritis (36). Interestingly, these two observations were subsequently found to be due to two quite separate activities of MUC1.

First, the ability of MUC1 to reduce H. pylori colonization was shown to be related to epithelial MUC1 acting as a releasable decoy (33) (Figure 1E). Specifically, H. pylori binding to MUC1 on epithelial cells triggers the release of the extracellular mucin domain, effectively shedding the bacteria from the mucosal surface, thereby limiting its ability to adhere to the gastric epithelium.

In contrast however, it was recently shown that surprisingly, it is MUC1 expressed by immune cells that reduces the severity of H. pylori-induced gastritis (39). In particular, MUC1 suppresses IL-1β secretion by macrophages in response to H. pylori, and by doing so, protects against the development of atrophic gastritis, an important step on the path to gastric cancer (39). A key stage of IL-1β production involves activation of inflammasomes, multiprotein complexes that, when activated, produce active caspase-1 that converts zymogenic pro-IL-1β (as well as pro-IL-18) into active cytokine. While a number of inflammasome complexes are known, IL-1β secretion in response to H. pylori occurs via the NLRP3 inflammasome (53), an inflammasome unique in its requirement for NF-κB activation. MUC1 was shown to attenuate the NLRP3 inflammasome by suppressing
activation of TLR signaling at the initial steps (before IRAK4, the first kinase in the TLR pathway) (Figure 1F) (39).

Thus, MUC1 is a key host factor that can both restrict *H. pylori* attachment to epithelial cells and prevent activation of the NLRP3 inflammasome in immune cells, thereby inhibiting activation of innate immunity via two distinct mechanisms.

_Peroxisome proliferator-activated receptor-γ_

Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors that belong to the nuclear hormone receptor family. Once activated, PPAR translocates to the nucleus, where it binds to a particular DNA motif (the peroxisome proliferator responsive element, PPRE) of target genes, upregulating their expression. The PPAR family comprise of 3 subtypes (PPAR-α, β and γ), of which PPAR-γ has been most studied during *H. pylori* infection.

Evidence suggests a role for PPAR-γ in *H. pylori* infection in humans. PPAR-γ is upregulated in gastric biopsies from *H. pylori* infected individuals and levels significantly drop after antibiotic eradication (26). Furthermore, a polymorphism in the *PPARG* gene that results in reduced binding of PPAR-γ to PPRE is significantly associated with gastric adenocarcinoma in *H. pylori* positive patients (46). Experimentally, treatment with a synthetic PPAR-γ ligand in a rat model of acute gastric inflammation reduces gastritis severity (55), and *Pparg*<sup>−/−</sup> mice develop more tumours and succumbed to cancer death ahead of wildtype controls (34), demonstrating that PPAR-γ also has anti-tumorigenic activity.

The mechanism by which PPAR-γ limits *H. pylori* pathology is unclear, although treatment of human gastric epithelial cells with a PPAR-γ agonist attenuates *H. pylori*-induced NF-κB
activation (18) (Figure 1C), providing at least one mechanism via which PPAR-γ could suppress gastritis.

3) Host inhibition of the adaptive immune response to \textit{H. pylori}

After the innate response to \textit{H. pylori} is initiated, chronic gastritis is perpetuated by establishment of a mixed Th1 and Th17-type pro-inflammatory adaptive immune response. The host has also developed a number of mechanisms that, in most individuals, limit this adaptive response.

\textit{Protease Activated Receptor-1}

Pathogenic infection and ensuing inflammation commonly result in the release of proteases. These extracellular proteases can act as warning signals detected by Protease-Activated Receptors (PAR), G protein-coupled receptors expressed by a wide range of cells including epithelial and immune cells. PAR activation, which occurs following exposure to an appropriate, typically serine, protease induces cell signaling events with a range of potential effects including cell proliferation and cytokine secretion (56).

One such receptor, PAR1, has a potent role in protecting against \textit{H. pylori}-induced gastritis. Mice lacking PAR1 develop a markedly more severe \textit{H. pylori}-induced atrophic gastritis (62), and a polymorphism in PAR1 (the \textit{PAR1} IVSn-14 T allele) has been identified as a risk factor for \textit{H. pylori}-associated gastric cancer in humans (7). As the \textit{PAR1} IVSn-14 T allele variant is linked with reduced PAR1 expression (14), the association of this polymorphism with gastric cancer susceptibility may have resulted from decreased gastric PAR1 leading to a reduced ability to control excessive inflammation.
PAR1 potentially inhibits *H. pylori*-induced gastritis by effects on both epithelial and immune cells. PAR1 reduces the MIP-2α (a functional homologue of human IL-8) response of mouse gastric epithelial cells to *H. pylori* stimulation, which would be expected to limit neutrophil recruitment into the infected gastric mucosa (62). However, bone marrow chimera studies reveal that the dominant protective effect is mediated by PAR1 expressing immune cells (9). In particular, PAR1 is a potent suppressor of interferon regulatory factor 5 (IRF5) in macrophages (9) (Figure 1G). IRF5 is an important transcription factor involved in IL-12 and IL-23 secretion, key drivers of Th1 and Th17 acquired immune responses respectively (28). PAR1 activation prevented IRF5 induction in macrophages exposed to *H. pylori* with downstream effects on IFNγ and IL-17 responses *in vivo* (9). Hence, PAR1 appears to protect against *H. pylori*-induced gastritis by regulating IRF5, thereby restricting both Th1 and Th17 adaptive responses and limiting the development of severe gastric pathologies.

**Regulatory T cells**

Regulatory T cells (Tregs) are potentially the most important and certainly the best studied suppressors of *H. pylori* induced inflammation. Tregs are typically CD4⁺CD25⁺FOXP3⁺ cells that can be broadly divided into natural Tregs (nTregs) and inducible Tregs (iTregs); the former being nonspecific and developing in the thymus, while the latter develop from naïve T cells under certain circumstances (50). Typically, nTregs suppress other T cells via direct contact, in contrast to iTregs which typically suppress other cells by secreting regulatory cytokines including IL-10 (50).

Multiple studies have demonstrated the importance of Tregs in regulating *H. pylori* pathology. Tregs numbers increase in *H. pylori* infected patients, with an inadequate Treg response associated with increased disease severity (49). Primarily, these Tregs are recruited...
via the CCL20 chemokine, secreted by epithelial cells in response to *H. pylori* (11). Consistent with these human data, gastric Foxp3 mRNA levels increase following *H. pylori* infection of mice (47) and Foxp3+ Tregs develop in draining lymph nodes (41). Moreover, the adoptive transfer of splenocytes into T cell deficient mice resulted in a more severe *H. pylori*-induced gastritis if the cells were Treg depleted (48), as did Treg depletion of conventional mice by the injection of an anti-CD25 antibody prior to *H. pylori* infection (47), demonstrating a clear role for Tregs in suppressing *H. pylori* pathology.

The main mechanism by which Tregs reduces gastritis severity is most likely by secreting the potent immunosuppressive cytokine IL-10 (Figure 1H). In mice, particularly severe gastritis is observed in *Il10*−/− animals after infection (3, 8) and *Il10*−/− Tregs are largely incapable of suppressing *H. pylori* gastritis (30). IL-10 has also been shown to increase in humans during gastritis (5) and an association between a low IL-10 producing haplotype variation has been found with atrophic gastritis (15).

During *H. pylori* infection, several cytokines promote Treg development, including the pleiotropic cytokine TGFβ1 and IL-18 (Figure 1H). While TGFβ1 is an important driver of Treg development, it can also exert direct immunosuppressive activity on a variety of cells (31). TGFβ1 derived from both epithelial and dendritic cells can promote Treg development in response to *H. pylori* (4, 24). A *TGFB1* promoter SNP (-509C>T) that results in increased TGFβ1 production is negatively associated with gastric cancer in humans (23), demonstrating the potentially important protective role of this cytokine in humans.

IL-18 which matures via an inflammasome in a similar fashion to IL-1β, is another important promoter of Treg development during *H. pylori* infection (41). Mice which lack IL-18 develop more severe *H. pylori*-induced gastritis (21), and it has been shown that it is
specifically IL-18 from dendritic cells that is essential for *H. pylori* induction of protective Tregs (41).

CONCLUSION

This current review discusses host factors for which there is clear evidence of a role in restricting the severity of *H. pylori*-induced gastritis. Such factors have evolved in order to ensure the inflammatory response to this pathogen is regulated and disease does not ensue; in most cases this is successful. From the literature presented here, it is evident that most known innate regulators suppress inflammation primarily by restricting activation of NF-κB, while Tregs are a key negative regulator of the adaptive immune response to *H. pylori* infection. There are likely more protective host factors that contribute to this regulation; some possibilities include myeloid derived suppressor cells (12), regulatory B cells (52), matrix metalloproteinase-7 (27), calgranulin C (19) and microRNA-155 (65), not discussed in this mini-review as their roles remain controversial.

Currently, the only treatment option for *H. pylori* infection is antibiotic eradication therapy, but with the rise in antibiotic resistance and recurrence of infection, the failure rate of this therapy is increasing (17). Given that it is gastritis and not directly colonization that drives peptic ulcer and gastric cancer development, a feasible approach to managing these diseases in future could be by pharmacologically enhancing host regulatory factors to suppress gastritis. For this, discovering exactly how the host maintains inflammation in most individuals is an important initial step. Additionally, the identification of key gain or loss of function polymorphisms in regulatory host genes could be used clinically to help identify individuals at risk of disease and thus better target gastric cancer and/or peptic ulcer disease treatment strategies.
ACKNOWLEDGEMENTS

The authors are supported by the Victorian Government’s Operational Infrastructure Support Program. PS is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. PD is supported by a Victoria India Doctoral Scholarship.

REFERENCES


### Table1. The role of major host factors in regulating *H. pylori*-induced inflammation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Function</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucin6</td>
<td>Antibacterial</td>
<td>(25)</td>
</tr>
<tr>
<td>Human β defensin-2</td>
<td>Antibacterial</td>
<td>(40)</td>
</tr>
<tr>
<td>Cathelicidin LL-37</td>
<td>Antibacterial</td>
<td>(66)</td>
</tr>
<tr>
<td>Galectin-3</td>
<td>Antibacterial</td>
<td>(43)</td>
</tr>
<tr>
<td>Trefoil factor-1</td>
<td>Suppression of TNFR1/NF-κB signalling pathway</td>
<td>(57, 58)</td>
</tr>
<tr>
<td>Trefoil factor-2</td>
<td>Negative regulation of IL-1R/NF-κB signalling pathway</td>
<td>(16, 29)</td>
</tr>
<tr>
<td>Gastrokine 2</td>
<td>Mechanism unclear&lt;br&gt;Possibly via modulation of NF-κB activation</td>
<td>(37)</td>
</tr>
<tr>
<td>Mucin1</td>
<td>Limiting <em>H. pylori</em> colonization on epithelial surface&lt;br&gt;Restricting activation of TLR/NF-κB pathway to suppress IL-1β production</td>
<td>(6, 36, 39, 61)</td>
</tr>
<tr>
<td>Peroxisome proliferator-activated receptor-γ</td>
<td>Inhibition of NF-κB activation</td>
<td>(18, 46, 55)</td>
</tr>
<tr>
<td>Protease Activated Receptor-1</td>
<td>Restricts activation of Interferon regulatory factor 5 to limit induction of Th1 and Th17 responses</td>
<td>(9, 62)</td>
</tr>
<tr>
<td>Regulatory T cells</td>
<td>Suppression of Th1 and Th17 responses mediated via production of IL-10</td>
<td>(30, 47-49)</td>
</tr>
</tbody>
</table>
**Figure 1: Host factors that suppress Helicobacter pylori-induced inflammation.**

A) The inner mucus layer contains several bactericidal agents including MUC6, cathelicidin LL-37, human β defensin-2 and galectin-3 that can limit *H. pylori* growth, thereby reducing the activation of innate immune receptors on the epithelial surface. B) Trefoil factor 1 (TFF1) restrict tumor necrosis factor receptor 1 (TNFR1) signaling, which like C) Peroxisome proliferator-activated receptor-γ (PPAR-γ), suppresses the activation of nuclear transcription factor-κB (NF-κB), thus downregulating the production of pro-inflammatory cytokines. D) TFF2 is a negative regulator of IL-1R signaling cascade in macrophages. E) MUC1 on the apical epithelial surface limits *H. pylori* binding to epithelium by acting as a releasable decoy, while F) MUC1 in immune cells suppresses IL-1β production by restricting activation of the TLR/NF-κB pathway and the NLRP3 inflammasome. G) Protease-Activated Receptor 1 (PAR1) on immune cells negatively regulates interferon regulatory factor-5 (IRF5) in macrophages, suppressing transcription of the Th1- and Th17-inducing cytokines, IL-12 and IL-23. H) *H. pylori* activated dendritic cells produce IL-18 and TGFβ1 that promote the development of regulatory T cells, which also inhibit the Th1 and Th17 responses, although via production of immunosuppressive IL-10. I) GKN2 is a potent suppressor of *H. pylori*-induced gastritis, but the mechanism is yet to be elucidated.